N/A
OverallTickerSpark AI RatingN/A
Amgen(AMGN) looks like a high-quality large-cap biotech with a durable medium-term setup, but not a clean bargain. The core case rests on three facts. First, the business is still growing through patent expirations: Q1 2026 revenue rose to $8.618B from $8.149B, non-GAAP EPS increased to $5.15 from $4.90, and management raised 2026 revenue guidance to $37.1B-$38.5B while lifting non-GAAP EPS guidance to $21.70-$23.10. Second, the growth engine is broad rather than single-product dependent: six key growth drivers generated about 70% of Q1 sales and grew 24%, while 16 brands posted double-digit growth. Third, the pipeline has real optionality, especially MariTide in obesity, alongside continued momentum in Repatha, TEPEZZA, UPLIZNA, IMDELLTRA, and TEZSPIRE.
The counterweight is just as real. Amgen carries $54.6B of debt against $9.129B of cash at year-end 2025, Prolia and XGEVA are already in erosion after loss of exclusivity, and the IRS dispute described by management could become material if the draft notice were sustained. That leaves the stock in a familiar biotech middle ground: strong enough to justify a premium to slower pharma names, but not so cheap that investors get pipeline upside for free.
For a balanced, moderate-risk investor with a medium-term horizon, the setup supports a Buy rating. The investment appeal is not built on one heroic assumption. It is built on a diversified commercial base, strong cash generation, visible earnings growth, and a pipeline that can change the growth profile if MariTide and late-stage cardiovascular assets execute. The main reason not to get overly aggressive is valuation discipline: with trailing P/E at 24.3, forward P/E at 15.1, and a consensus target around $352.73, the stock already reflects a fair amount of that resilience.
Amgen(AMGN) is a U.S.-based biotechnology company founded in 1980 and listed on NASDAQ. It operates across General Medicine, Rare Disease, Inflammation, and Oncology, with roughly 40 products and 31,500 employees. The company discovers, develops, manufactures, and commercializes human therapeutics worldwide, selling through physicians, clinics, hospitals, dialysis centers, pharmacies, and wholesale distributors.
This is not a one-drug story. In 2025, Amgen generated $35.339B of revenue across a wide product base. The largest products were Prolia at $4.414B, Repatha at $3.016B, Otezla at $2.265B, Enbrel at $2.226B, EVENITY at $2.100B, XGEVA at $2.084B, and TEPEZZA at $1.903B. BLINCYTO, Nplate, Aranesp, KRYSTEXXA, TEZSPIRE, and Vectibix each contributed more than $1B. That spread matters. It reduces dependence on any single molecule and gives management more room to absorb patent cliffs.
The business mix has also shifted meaningfully in the last three years. Revenue rose from $28.19B in 2023 to $33.42B in 2024 and then to $36.74B in 2025. That is not the profile of a company simply milking legacy biologics. It is the profile of a company replacing aging revenue streams with newer growth brands, acquired assets, and biosimilars. Management described 2026 as a "springboard year," and the Q1 numbers support that framing more than they challenge it.
The strategic identity is clear. Amgen is trying to be a scale biotech with pharma-like durability: broad commercial reach, heavy biologics manufacturing capability, steady cash generation, and enough pipeline depth to keep the growth profile from flattening out. That model can work well for moderate-risk investors because it avoids the binary risk that defines smaller biotech names.
Amgen does not report classic operating segments the way an industrial company would, but the commercial portfolio can still be grouped into practical buckets. In Q1 2026, management said the six key growth drivers generated $5.6B of sales, represented almost 70% of total product sales, and grew 24% YoY. Those drivers include Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, and Biosimilars.
General Medicine remains a large earnings base. Repatha is now one of the clearest growth engines, while Prolia and XGEVA are moving the other way after loss of exclusivity. In 2025, Prolia still generated $4.414B and XGEVA $2.084B, so erosion here is financially meaningful. The company is effectively trying to outrun that pressure with faster-growing assets elsewhere. That race matters more than any single quarter.
Rare Disease is becoming a more important contributor. Management said the rare disease portfolio grew 25% YoY to $1.2B in Q1 2026, with UPLIZNA up 188% to $262M and TAVNEOS up 32% to $119M. TEPEZZA, while often discussed on its own because of its profile, also fits the broader rare and specialty disease playbook. These products tend to serve concentrated patient populations, support premium pricing, and reward strong access infrastructure.
Innovative Oncology is another bright spot. The oncology portfolio, including BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, LUMAKRAS, and Nplate, grew 25% YoY to $1.8B in Q1 2026. BLINCYTO alone delivered $415M in the quarter, up 12%, while IMDELLTRA produced $258M and is expanding across care settings. Oncology is crowded, but it is also where differentiated efficacy can move the needle quickly.
Biosimilars are the quiet strategic hedge. Management said the biosimilar portfolio generated $835M in Q1 2026 and grew 14% YoY in the transcript, while the investor presentation cited 25% YoY growth for the portfolio. The exact portfolio growth figure differs across company materials, but both point in the same direction: biosimilars are contributing real scale. PAVBLU alone delivered $280M in Q1. That gives Amgen an unusual position in biotech, facing biosimilar erosion in mature brands while also monetizing the same industry trend on offense.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Repatha is the flagship product to watch because it combines commercial momentum, clinical differentiation, and label-expansion style optionality. In 2025, Repatha generated $3.016B of revenue, up from $2.222B in 2024 and $1.635B in 2023. In Q1 2026, sales reached $876M, up 34% YoY. That is not incremental growth. That is acceleration.
The commercial case is tied directly to clinical data. Management highlighted a VESALIUS-CV subgroup analysis in 3,655 high-risk diabetes patients without known significant atherosclerosis, where Repatha showed a 31% reduction in major adverse cardiovascular events. Murdo Gordon also said Repatha is now the only PCSK9 inhibitor with positive outcomes data in both high-risk primary and secondary prevention patients. In biotech, that kind of outcomes evidence is the difference between a good drug and a drug that changes prescribing behavior.
Guideline support adds another layer. Management said the ACC/AHA updated dyslipidemia guidelines to reinforce earlier risk identification, lower LDL-C targets, and earlier use of therapies like Repatha. The company also launched a simplified cash-pay option in the U.S. That combination of evidence, access, and guideline momentum is exactly how a specialty drug moves from niche to standard practice.
There are other flagship candidates inside the portfolio. TEPEZZA grew 29% in Q1 2026 to $490M and has treated more than 25,000 U.S. patients since launch. EVENITY rose 27% to $562M and holds a 65% share of the U.S. bone builder market. TEZSPIRE reached $343M, up 20%. But Repatha stands out because it already has scale, it is growing fast, and the clinical story still has room to broaden adoption. If Amgen has a current commercial spearhead, this is it.
Amgen’s moat comes from a combination of portfolio breadth, biologics manufacturing capability, payer and provider relationships, and a pipeline that is deeper than the market sometimes gives it credit for. The company is not relying on one moonshot. It is running multiple shots on goal across obesity, cardiovascular disease, oncology, inflammation, and rare disease.
MariTide is the most important innovation lever. Management announced new Phase III studies in Q1 2026, including MARITIME-Switch and two chronic weight management maintenance extensions. The core differentiation claim is convenience: switching from weekly injectables to dosing every 8 or 12 weeks. In plain English, Amgen is trying to compete in obesity with a product designed to reduce treatment burden, not just chase efficacy headlines.
That matters because persistence is a real commercial issue in obesity therapy. James Bradner said MariTide’s antibody-peptide conjugate design supports monthly or less frequent dosing and that three-step dose escalation reduced nausea and vomiting versus prior experience. If that profile holds in late-stage development, Amgen has a differentiated angle in one of the largest therapeutic markets in the industry.
The innovation story extends beyond MariTide. Olpasiran continues in Phase III and recently initiated OCEAN(a)-CCTA. TEPEZZA posted positive Phase III topline data for subcutaneous administration via an on-body injector. Dazodalibep has two fully enrolled Phase III Sjögren’s studies expected to complete later in 2026. IMDELLTRA is moving into earlier lines of therapy in small cell lung cancer. This is a pipeline with breadth, not just noise.
Amgen is also leaning into AI in a way that is more operational than promotional. Management said antibody lead optimization accelerated by 50%, clinical site selection improved enrollment rates by up to threefold in some cases, and AI-enabled automation reduced production line clearance time at one manufacturing site from about 30 minutes to about 2 minutes per batch run. Plenty of companies talk about AI. Those are actual operating metrics.
Operations are a real competitive asset for Amgen because biologics manufacturing is hard, regulated, and expensive to replicate. The company’s commercial model depends on reliable supply across specialty products, biosimilars, and future launches. Management highlighted manufacturing investments across U.S. sites in Ohio, North Carolina, and Puerto Rico, with Q1 2026 capital expenditures of $700M and full-year 2026 capex expected around $2.6B.
That spending is not cosmetic. Peter Griffith said the company is scaling manufacturing capacity for volume growth, including MariTide’s launch. In biotech, manufacturing often becomes the bottleneck right when demand arrives. Amgen is trying to solve that before it becomes a problem. That is expensive in the short run but strategically sensible.
Supply reliability also shows up in product adoption. Management said retina specialists value PAVBLU’s ready-to-use prefilled syringe and Amgen’s track record of reliable biologics supply. More than 1,800 U.S. sites now administer IMDELLTRA, with most doses delivered in community settings. Those details sound operational, because they are. They also translate into commercial traction.
The main operational watchpoint is cost mix. Management said non-GAAP cost of sales as a percentage of product sales was 19.5% in Q1 2026, pressured by higher profit-share and royalty expenses and changes in sales mix, and expects those factors to continue affecting future quarters. So the supply chain is a strength, but not a free one.
Amgen operates in large and growing therapeutic markets, but the practical near-term opportunity is narrower than the broad biotechnology TAM figures often cited. The company’s real addressable battlegrounds are obesity and metabolic disease, cardiovascular risk reduction, inflammation, oncology, bone health, rare disease, and biosimilars.
The market backdrop is favorable where Amgen is strongest. Cardiovascular disease remains a massive undertreated category, and Repatha’s outcomes data plus guideline support can expand use in high-risk primary prevention. Bone health also remains underpenetrated. Management said more than 90% of the 2 million women at very high fracture risk remain untreated, which helps explain why EVENITY still has room to grow despite already leading the U.S. bone builder market with 65% share.
Rare disease and specialty immunology markets also reward commercial focus and access execution more than brute-force primary care scale. TEPEZZA, UPLIZNA, and TAVNEOS fit that pattern. In oncology, Amgen is competing in narrower but high-value settings where differentiated efficacy can support durable adoption, especially for assets like BLINCYTO and IMDELLTRA.
The obesity market is the wild card. Management is positioning MariTide around less frequent dosing and better persistence, while company materials note that only 1%-3% of eligible U.S. adults are prescribed medication for chronic weight management. That is a huge runway if the product profile holds up. It is also the reason investors are willing to assign strategic value to a pipeline asset that is not yet commercial.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Amgen’s customers are mainly healthcare providers and institutions rather than end consumers. The company serves physicians and clinics, dialysis centers, hospitals, pharmacies, and wholesale distributors. That means prescribing behavior, reimbursement, site-of-care logistics, and specialist education matter as much as raw clinical efficacy.
The customer base varies by product. Repatha depends on cardiologists and primary care physicians. TEZSPIRE depends on pulmonology and allergy specialists. TEPEZZA is seeing increased prescribing from endocrinologists and a broader specialist base. UPLIZNA adoption is being led by neurologists, rheumatologists, GI specialists, and nephrologists depending on indication. IMDELLTRA is spreading through both academic and community oncology settings.
This matters because Amgen’s commercial advantage is partly about navigating fragmented specialist channels. Management repeatedly emphasized patient services, broad payer coverage, direct access models, and removing operational barriers in practice settings. In specialty pharma, the molecule opens the door, but access and workflow often decide how wide it swings.
Amgen competes against a deep bench of large-cap biopharma companies, including AbbVie, Johnson & Johnson, Eli Lilly, Novartis, Regeneron, Sanofi, AstraZeneca, GSK, Roche, Merck, Pfizer, Bristol Myers Squibb, Takeda, and Sandoz. The competition is product-specific, mechanism-specific, and increasingly convenience-specific.
Repatha competes with Praluent from Regeneron/Sanofi and Leqvio from Novartis. TEZSPIRE competes with Dupixent, Fasenra, Xolair, and Nucala. Otezla competes with a crowded psoriasis field including Skyrizi, Tremfya, Taltz, Cosentyx, and Sotyktu. Nplate competes with Promacta/Revolade. Vectibix faces a broad oncology field including Avastin, Keytruda, and Erbitux. Enbrel competes with Humira, Hyrimoz, and Rinvoq.
The pressure on Prolia and XGEVA from biosimilars is already visible. Management said the pair delivered $1.1B in Q1 2026, down 32% YoY, and expects accelerated erosion through the rest of 2026. That is the blunt end of the biotech business model: great products eventually attract competition, and the revenue line does not negotiate.
Amgen’s defense is differentiation plus diversification. Repatha’s outcomes data, EVENITY’s market leadership, TEPEZZA’s efficacy and patient services, TEZSPIRE’s mechanism, and IMDELLTRA’s emerging standard-of-care status all support that defense. The company also competes as a biosimilar maker, which softens the industry-wide shift toward lower-cost biologics. It is not a perfect hedge, but it is better than standing still while the tide comes in.
Biotech is less cyclical than many sectors, and Amgen’s beta of 0.465 reflects that defensive profile. Demand for oncology, rare disease, cardiovascular, and bone health therapies does not depend much on consumer confidence. That makes the stock useful in a moderate-risk portfolio, especially when macro conditions are noisy.
The bigger macro forces here are policy and regulation. FDA efforts to simplify biosimilar development and reduce development burden should increase competitive pressure over time. That is a headwind for mature biologics like Prolia and XGEVA, but also an opportunity for Amgen’s own biosimilar business. In other words, the company is exposed on both sides of the policy ledger.
Geographically, Amgen’s manufacturing footprint includes Puerto Rico, which also matters in the company’s tax structure. That connects directly to the IRS dispute management discussed in Q1 2026. Peter Griffith said the company received a draft notice of proposed adjustment for 2016-2018 related primarily to the allocation of profits between the U.S. and Puerto Rico, and that if sustained in full it could have a material impact on financial statements. This is not a day-to-day operating issue, but it is a real risk factor.
The broader healthcare policy backdrop remains a constant pressure point around pricing, reimbursement, and access. Amgen’s answer has been to emphasize patient services, direct cash-pay options for select products, and scale in payer relationships. That does not remove policy risk, but it gives the company more tools than a smaller biotech would have.
Amgen carries $54.6B of debt against $9.129B of cash, and the IRS dispute could become material if the draft notice is sustained.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessQ1 2026 revenue rose to $8.618B from $8.149B while non-GAAP EPS increased to $5.15 from $4.90, showing the core business is still expanding.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessManagement lifted 2026 revenue guidance to $37.1B-$38.5B and non-GAAP EPS guidance to $21.70-$23.10 after a strong first quarter.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessTrailing P/E is 24.3 and forward P/E is 15.1, so the shares already price in a fair amount of the company’s resilience.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessA consensus target around $352.73 suggests limited upside if execution stays on track, which is why valuation discipline still matters.
Unlock the full analysis
Subscribers get the complete breakdown — grades, rationale, and specific targets.
Get Full AccessAmgen(AMGN) is in a better position than the usual patent-expiration narrative suggests. Revenue is growing, earnings are improving, guidance has been raised, and the company has multiple products with real commercial momentum. Repatha is scaling into a larger cardiovascular franchise, TEPEZZA and UPLIZNA are strengthening the rare-disease mix, oncology is contributing meaningful growth, and MariTide gives the pipeline a genuine shot at changing the company’s long-term growth profile.
The market is not missing all of that. That is why this is a Buy, not a Strong Buy. The debt load is heavy, the IRS dispute is a live risk, and Prolia/XGEVA erosion will continue to pressure the base business. But for a moderate-risk investor looking 12-36 months out, Amgen offers something valuable: a biotech name with enough scale and cash flow to absorb shocks, and enough innovation to still matter. That combination is harder to find than the sector’s daily noise would suggest.
Yes, AMGN looks like a Buy for investors who want large-cap biotech exposure with a medium-term horizon. The company is growing through patent expirations, raising guidance, and seeing broad momentum across Repatha, rare disease, oncology, and biosimilars.
Amgen's fair value is $352.73. That view reflects the consensus target cited in the report, alongside a forward P/E of 15.1, a trailing P/E of 24.3, and the fact that six key growth drivers already account for about 70% of product sales while growing 24% year over year.
Because the growth base is broad enough to offset erosion from Prolia and XGEVA. In Q1 2026, six key growth drivers generated about $5.6B of sales and grew 24%, while rare disease and oncology each grew 25% year over year.
MariTide is the biggest pipeline optionality, especially in obesity, where a successful launch could materially change the growth profile. Repatha is also already accelerating, with Q1 2026 sales of $876M, up 34% year over year, and outcomes data that supports broader adoption.
The biggest risks are leverage, patent erosion, and the IRS dispute. Amgen has $54.6B of debt versus $9.129B of cash, Prolia and XGEVA are already declining after loss of exclusivity, and management flagged a tax dispute that could become material if sustained.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access
Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.
Energy earnings stole the spotlight as Valero, ConocoPhillips, and Exxon Mobil topped estimates, while Linde and Dominion Energy showed steady execution. But the market’s reaction was mixed, reminding investors that a strong quarter does not always translate into a strong stock move.
U.S. growth held up, but inflation stayed stubborn and layoffs remained scarce. Stronger-than-expected spending, a hot PCE reading, and a jump in ISM prices reinforced the Fed’s higher-for-longer stance, even as markets briefly rallied on softer GDP and earnings support.